Ep 79: coBRIM, COMBI-d 5-year follow-up

Summary

In this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of studies such as coBRIM, COMBI-d, and how those compare to 5-year benchmarks from the COLUMBUS study. They explore subgroups and characteristics of favorable (and durable) response, the role of MEK inhibitors on immune activation, and a potential fellow's project (looking at you, Rob?).

Keywords

Melanoma, targeted therapy, co-BRIM, COMBI-d, COLUMBUS, immunotherapy, BRAF MEK inhibitors, overall survival, progression-free survival, patient outcomes, cohorts, LDH, organ sites

Takeaways

MEK inhibitors have a complex role in immune response.

Normal LDH levels correlate with better patient outcomes.

Immunotherapy and targeted therapy can have overlapping patient populations.

Sound Bites

"We thought we'd do more targeted therapy"

"Normal LDH is doing better."

"Long-term follow-up for targeted therapy."

Chapters

00:00 Will he or won't he ... James awaits invitation to film premiere

04:26 coBRIM 5y FU

11:56 COMBI-d 5y FU

13:19 LDH subgroups

17:26 Normal LDH & <3 organ sites of metastasis

18:07 Invalid analysis & graph ... tsk tsk NEJM

22:36 Fact Check

22:40 What's the color of James' t-shirt?

25:34 Five-Year Results of BRAF Targeted Therapies

28:37 Cure Potential of Adjuvant Targeted Therapy

31:34 MEK Inhibition and Immune Activation